MORPHOSYS AG | 85.16 / +0.52% |
Date/Time | 02/25 / 17:32 |
Chg. / Chg.(%) | 0.44 / +0.52% |
Bid | - |
Ask | - |
Open | 86.30 |
Previous Close | 84.72 |
High | 86.30 |
Low | 84.46 |
Volume [EUR] | 6,778.80 |
Volume [Units] | 80 |
Price fixings | 4 |
ISIN | DE0006632003 |
Security | MOR |
Exchange | Vienna Global Market |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
TradeGate | 84.580 | ![]() |
598 |
München | 84.54 | ![]() |
100 |
gettex | 84.580 | ![]() |
10 |
Frankfurt | 84.0400 | ![]() |
0 |
Hannover | 84.02 | ![]() |
0 |
Berlin | 84.02 | ![]() |
0 |
Hamburg | 84.02 | ![]() |
0 |
Düsseldorf | 84.02 | ![]() |
0 |
Lang & Schwa.. | 83.940 | ![]() |
|
Stuttgart | 84.080 | ![]() |
|
Xetra | 85.36 | ![]() |
138,658 |
Cboe Europe .. | 85.16 | ![]() |
28,145 |
Turquoise | 85.18 | ![]() |
13,148 |
London Inter.. | 84.88 | 5,662 | |
Vienna Globa.. | 85.16 | ![]() |
80 |
Cboe Europe .. | 85.56 | 495 | |
Cboe Europe .. | 85.92 | 22 | |
Nasdaq Other.. | 113.1500 | 100 | |
EUREX | Options |
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire